| TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era (NCT05752019) | Erasmus Medical Center | 2022-03-21 |
| Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial (NCT04620486) | Massachusetts General Hospital | 2020-10-20 |
| Drug-drug Interaction Study of Gepotidacin (NCT04493931) | GlaxoSmithKline | 2020-08-14 |
| Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects (NCT04079790) | GlaxoSmithKline | 2019-09-04 |
| Gram-negative Bacilli and MRSA Screening in ICU in China (NCT04310722) | Sir Run Run Shaw Hospital | 2019-08-06 |
| Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients (NCT03557840) | Paul M. Tulkens | 2019-04-01 |
| Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis) (NCT03568942) | GlaxoSmithKline | 2018-07-23 |
| Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function (NCT03562117) | GlaxoSmithKline | 2018-06-14 |
| Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions (NCT03408392) | GlaxoSmithKline | 2018-02-06 |
| A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions (NCT03329547) | GlaxoSmithKline | 2018-01-11 |
| Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects (NCT03150082) | GlaxoSmithKline | 2017-08-01 |
| Thermal Images on Smartphones to Diagnose Bacterial Pneumonia in Children in Pakistan (NCT02908399) | Massachusetts General Hospital | 2016-10-01 |
| To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects. (NCT02853435) | GlaxoSmithKline | 2016-08-04 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830 (NCT02751424) | GlaxoSmithKline | 2016-06-13 |
| Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia (NCT02778672) | Boston University | 2016-05-01 |
| Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India (NCT02381431) | Massachusetts General Hospital | 2015-03-01 |
| Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed (NCT02339155) | Emergent BioSolutions | 2015-02-24 |
| Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections (NCT02292498) | Massachusetts General Hospital | 2014-11-01 |
| A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women (NCT01953809) | GlaxoSmithKline | 2014-08-01 |
| A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (NCT01803399) | GlaxoSmithKline | 2014-08-01 |
| Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections (NCT02045797) | GlaxoSmithKline | 2014-03-24 |
| Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects (NCT02045849) | GlaxoSmithKline | 2014-01-28 |
| To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 (NCT01934205) | GlaxoSmithKline | 2013-09-25 |
| A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects (NCT01818011) | GlaxoSmithKline | 2013-08-07 |
| A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects (NCT01648179) | GlaxoSmithKline | 2012-03-01 |
| WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics (NCT01587768) | GlaxoSmithKline | 2011-11-01 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects (NCT01610388) | GlaxoSmithKline | 2011-09-13 |
| Amoxicillin Bioequivalence Study Brazil - Fast (NCT01431989) | GlaxoSmithKline | 2011-05-27 |
| A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects (NCT01262885) | GlaxoSmithKline | 2010-10-07 |
| A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc. (NCT01039610) | GlaxoSmithKline | 2009-11-01 |
| In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance (NCT01132417) | King Faisal University | 2009-09-01 |
| A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects (NCT00896558) | GlaxoSmithKline | 2009-05-11 |
| Relative Bioavailability Study in Healthy Subjects (NCT00924911) | GlaxoSmithKline | 2009-04-27 |
| Single Dose Escalation First Time in Human PK Study (NCT00828867) | GlaxoSmithKline | 2008-11-14 |
| Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus (NCT00539994) | GlaxoSmithKline | 2007-09-01 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416 (NCT00680485) | GlaxoSmithKline | 2007-06-01 |
| A Three-Part Study Of GSK580416 In Healthy Subjects (NCT00427141) | GlaxoSmithKline | 2006-10-01 |
| Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT00259909) | GlaxoSmithKline | 2005-11-02 |
| Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) (NCT00358371) | GlaxoSmithKline | 2005-01-06 |